Wedbush Securities’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $319K | Buy |
15,960
+5,360
| +51% | +$94.7K | 0.01% | 912 |
|
|
2026
Q1 | $172K | Hold |
10,600
| – | – | 0.01% | 1158 |
|
|
2025
Q4 | $178K | Sell |
10,600
-350
| -3% | -$5.88K | 0.01% | 1133 |
|
|
2025
Q3 | $170K | Sell |
10,950
-1,000
| -8% | -$13.7K | 0.01% | 1091 |
|
|
2025
Q2 | $153K | Buy |
11,950
+200
| +2% | +$2.47K | 0.01% | 1082 |
|
|
2025
Q1 | $149K | Buy |
+11,750
| New | +$159K | 0.01% | 1037 |
|
|
2024
Q4 | – | Sell |
-16,273
| Closed | -$245K | – | 1165 |
|
|
2024
Q3 | $245K | Sell |
16,273
-400
| -2% | -$6.05K | 0.01% | 904 |
|
|
2024
Q2 | $236K | Buy |
16,673
+1,261
| +8% | +$17.1K | 0.01% | 987 |
|
|
2024
Q1 | $210K | Sell |
15,412
-4,700
| -23% | -$65K | 0.01% | 1070 |
|
|
2023
Q4 | $271K | Sell |
20,112
-2,624
| -12% | -$32.3K | 0.01% | 814 |
|
|
2023
Q3 | $284K | Buy |
22,736
+3,000
| +15% | +$39.5K | 0.01% | 754 |
|
|
2023
Q2 | $267K | Buy |
19,736
+1,724
| +10% | +$23.8K | 0.01% | 810 |
|
|
2023
Q1 | $251K | Buy |
18,012
+1,250
| +7% | +$17.9K | 0.01% | 822 |
|
|
2022
Q4 | $238K | Buy |
16,762
+2,450
| +17% | +$35.5K | 0.01% | 834 |
|
|
2022
Q3 | $196K | Buy |
14,312
+318
| +2% | +$4.75K | 0.01% | 902 |
|
|
2022
Q2 | $199K | Buy |
13,994
+824
| +6% | +$12.4K | 0.01% | 929 |
|
|
2022
Q1 | $218K | Buy |
13,170
+2,975
| +29% | +$51.2K | 0.01% | 948 |
|
|
2021
Q4 | $196K | Buy |
10,195
+109
| +1% | +$2.19K | 0.01% | 1062 |
|
|
2021
Q3 | $210K | Sell |
10,086
-17
| -0.2% | -$364 | 0.01% | 1042 |
|
|
2021
Q2 | $217K | Buy |
+10,103
| New | +$204K | 0.01% | 1026 |
|
|
2019
Q2 | – | Sell |
-10,913
| Closed | -$187K | – | 1011 |
|
|
2019
Q1 | $187K | Buy |
+10,913
| New | +$188K | 0.02% | 792 |
|
|
2018
Q4 | – | Sell |
-11,707
| Closed | -$239K | – | 882 |
|
|
2018
Q3 | $239K | Buy |
+11,707
| New | +$233K | 0.03% | 686 |
|
|
2016
Q3 | – | Sell |
-10,104
| Closed | -$174K | – | 842 |
|
|
2016
Q2 | $174K | Buy |
+10,104
| New | +$186K | 0.03% | 648 |
|
|
2016
Q1 | – | Sell |
-12,059
| Closed | -$285K | – | 775 |
|
|
2015
Q4 | $285K | Buy |
12,059
+1,601
| +15% | +$39.7K | 0.05% | 426 |
|
|
2015
Q3 | $235K | Sell |
10,458
-589
| -5% | -$16.5K | 0.05% | 465 |
|
|
2015
Q2 | $312K | Buy |
11,047
+2,105
| +24% | +$58.3K | 0.06% | 412 |
|
|
2015
Q1 | $247K | Buy |
+8,942
| New | +$244K | 0.04% | 495 |
|
Other funds holding HQL
Wedbush Securities's HQL Position: Q2 2026 in Review
Wedbush Securities increased its abrdn Life Sciences Investors (HQL) stake by 51% in Q2 2026, buying an estimated $94.7K and bringing the position to 15,960 shares worth $319K. The position accounts for 0.01% of the portfolio, ranked #912.
Wedbush Securities first reported a position in HQL in Q1 2015 and has held it in 27 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.
- Wedbush Securities held 15,960 shares of abrdn Life Sciences Investors worth $319K as of Q2 2026.
- Wedbush Securities bought 5,360 abrdn Life Sciences Investors shares in Q2 2026, an estimated $94.7K.
- abrdn Life Sciences Investors made up 0.01% of Wedbush Securities's portfolio in Q2 2026, its #912 holding.
- Wedbush Securities first reported a position in abrdn Life Sciences Investors in Q1 2015 and has held it in 27 quarters since.
- 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.
Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.